AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31119692 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fasting versus postprandial oral administration of esaxerenone
Number of subjects: 24
Study 31119692 — intervention group
Group type: COMPARATOR
Intervention: Overall safety assessment
Number of subjects: 24
Study 28130796 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu labeling (calorie information provided)
Number of subjects: 716
Study 28130796 — intervention group
Group type: COMPARATOR
Intervention: No menu labeling (calorie information not provided)
Number of subjects: 716
Study 25491433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day
Number of subjects: 1987
Study 25491433 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg/day
Number of subjects: 1987
Study 23317717 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminar flow theatre environment
Number of subjects: 170
Study 23317717 — intervention group
Group type: COMPARATOR
Intervention: Non-laminar flow theatre environment
Number of subjects: 170
Study 20643699 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (n=12)
Number of subjects: 20
Study 20643699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 20
Study 20635756 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA (tenecteplase)
Number of subjects: 0
Study 16754836 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXB-A (lower dose)
Number of subjects: 12
Study 16754836 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXB-A
Number of subjects: 12
Study 16754836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15086665 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Velocity Exercise Specific to Task (InVEST), n=11
Number of subjects: 21
Study 15086665 — intervention group
Group type: COMPARATOR
Intervention: Control exercise group (n=10)
Number of subjects: 21
Study 12297781 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic radial array echoendoscope
Number of subjects: 14
Study 12297781 — intervention group
Group type: COMPARATOR
Intervention: Mechanical radial echoendoscope
Number of subjects: 14
Study 10203647 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group (home uterine activity monitoring)
Number of subjects: 162
Study 10203647 — intervention group
Group type: COMPARATOR
Intervention: Control group (unmonitored)
Number of subjects: 162
Study 10203647 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group
Number of subjects: 162
Study 10203647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study 7583611 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air (group I)
Number of subjects: 70
Study 7583611 — intervention group
Group type: COMPARATOR
Intervention: 80% oxygen (group II)
Number of subjects: 70
Study 2178941 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral estrogen (polyestradiol phosphate 80 or 160 mg i.m. monthly)
Number of subjects: 11
Study 2178941 — intervention group
Group type: COMPARATOR
Intervention: Bilateral subcapsular orchiectomy
Number of subjects: 11
Study 760745 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperidine (5 mg) administered intravenously to five patients after a single dose of PPZ-enanthate i.m.
Number of subjects: 26
Study 760745 — intervention group
Group type: COMPARATOR
Intervention: Oral PPZ treatment in fourteen patients with addition of biperidine or orphenadine given for 3 weeks in fixed oral doses.
Number of subjects: 26
Study 760745 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant antiparkinson therapy with PPZ.
Number of subjects: 26
Study 6668666 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 0.5g/m2 orally 4 hours before irradiation
Number of subjects: 147
Study 6668666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 6668666 — intervention group
Group type: EXPERIMENTAL
Intervention: RF hyperthermia combined with radiation
Number of subjects: 147
Study 28464331 — intervention group
Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 128
Study 28464331 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi DBS
Number of subjects: 128
Study 28464331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GPi and STN DBS
Number of subjects: 128
Study 25405562 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body MTV (Metabolic Tumor Volume)
Number of subjects: 17
Study 25405562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MTV (<37.2 mL)
Number of subjects: 17
Study 25405562 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease burden outside the abdomen <35%
Number of subjects: 17
Study 24958585 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized caregiver-mediated intervention (CMM)
Number of subjects: 112
Study 24958585 — intervention group
Group type: COMPARATOR
Intervention: Group caregiver education
Number of subjects: 112
Study 23193746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% minoxidil lotion (MNX)
Number of subjects: 40
Study 23193746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 3% minoxidil and 0.1% finasteride lotion (MFX)
Number of subjects: 40
Study 20233137 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 69
Study 20233137 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 69
Study 18607268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum and fructooligosaccharides (synbiotic preparation)
Number of subjects: 31
Study 18607268 — intervention group
Group type: COMPARATOR
Intervention: Dextrose saline placebo
Number of subjects: 31
Study 16491681 — intervention group
Group type: EXPERIMENTAL
Intervention: Men tested by a female experimenter
Number of subjects: 64
Study 16491681 — intervention group
Group type: COMPARATOR
Intervention: Men tested by a male experimenter
Number of subjects: 64
Study 16491681 — intervention group
Group type: EXPERIMENTAL
Intervention: Women tested by a female experimenter
Number of subjects: 64
Study 16491681 — intervention group
Group type: COMPARATOR
Intervention: Women tested by a male experimenter
Number of subjects: 64
Study 12056770 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based digital records (50 students)
Number of subjects: 99
Study 12056770 — intervention group
Group type: COMPARATOR
Intervention: Traditional orthodontic records (49 students)
Number of subjects: 99
Study 11220538 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 0
Study 11220538 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 0
Study 11220538 — intervention group
Group type: COMPARATOR
Intervention: VDD pacing
Number of subjects: 0
Study 7720150 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane 0.3%
Number of subjects: 40
Study 7720150 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane 0.6%
Number of subjects: 40
Study 7720150 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane 0.9%
Number of subjects: 40
Study 7720150 — intervention group
Group type: COMPARATOR
Intervention: control (fentanyl-nitrous oxide anaesthesia)
Number of subjects: 40
Study 1922206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg per day
Number of subjects: 40
Study 1922206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 1.25 mg per day
Number of subjects: 40
Study 1922206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg per day
Number of subjects: 40
Study 1922206 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 0.1 mg twice a week
Number of subjects: 40
Study 1922206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7065386 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium-coated polyester foil
Number of subjects: 80
Study 7065386 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion solutions warmed to body temperature and operation theatre temperature raised to 22-24 degrees C
Number of subjects: 80
Study 31900273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi exercise (12-week programme, 60 min per session, twice weekly)
Number of subjects: 66
Study 31900273 — intervention group
Group type: COMPARATOR
Intervention: Balance and postural control training (12-week programme, 60 min per session, twice weekly)
Number of subjects: 66
Study 31900273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi exercise
Number of subjects: 66
Study 31900273 — intervention group
Group type: COMPARATOR
Intervention: Balance and postural control training
Number of subjects: 66
Study 30348962 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound (RTUS) guidance
Number of subjects: 80
Study 30348962 — intervention group
Group type: COMPARATOR
Intervention: Conventional landmark (CL) technique
Number of subjects: 80
Study 28135963 — intervention group
Group type: EXPERIMENTAL
Intervention: operation‐unit‐based integrated design
Number of subjects: 42
Study 28135963 — intervention group
Group type: COMPARATOR
Intervention: action‐based integrated design
Number of subjects: 42
Study 28135963 — intervention group
Group type: COMPARATOR
Intervention: existing separated‐displays design
Number of subjects: 42
Study 25672925 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO prehospital stroke concept (IV thrombolysis)
Number of subjects: 0
Study 25672925 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 24074720 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training program for quadriceps (n=16), 12 weeks, 3 times per week, at angular velocity 150°/s, concentric mode of contraction, 3 sets/day, 3 min rest between sets.
Number of subjects: 33
Study 24074720 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17), home based physical therapy exercise program without isokinetic.
Number of subjects: 33
Study 22372774 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide (OM/AML/HCTZ)
Number of subjects: 2112
Study 19732641 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 40 degrees C)
Number of subjects: 32
Study 19732641 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 25 degrees C)
Number of subjects: 32
Study 17263634 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV/r 800/100 mg bid
Number of subjects: 70
Study 15106814 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 2 mg (T)
Number of subjects: 438
Study 15106814 — intervention group
Group type: COMPARATOR
Intervention: Verapamil SR/trandolapril 180/2 mg (V + T)
Number of subjects: 438
Study 15106814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 438
Study 11805389 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (125 IU/kg, once weekly)
Number of subjects: 194
Study 11805389 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (250 IU/kg, once weekly)
Number of subjects: 194
Study 11805389 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 194
Study 9746884 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (20 million KIU given over 30 h)
Number of subjects: 48
Study 9746884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 48
Study 7872041 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 144
Study 7872041 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 144
Study 7872041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Remoxipride and Thioridazine
Number of subjects: 144
Study 3258815 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid tablets 300 mg twice daily
Number of subjects: 30
Study 3258815 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid sustained action (SA) capsules 600 mg once daily
Number of subjects: 30
Study 3258815 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin sustained release (SR) capsules 75 mg once daily
Number of subjects: 30
Study 3258815 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid SA capsules
Number of subjects: 30
Study 3258815 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin SR capsules
Number of subjects: 30
Study 3258815 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid tablets
Number of subjects: 30
Study 31599035 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerosity training (apple-collecting game)
Number of subjects: 80
Study 31599035 — intervention group
Group type: COMPARATOR
Intervention: English dictation task (control group)
Number of subjects: 80
Study 31554422 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete angiographically guided revascularization
Number of subjects: 306
Study 31554422 — intervention group
Group type: COMPARATOR
Intervention: Stress echocardiography-guided revascularization
Number of subjects: 306
Study 27600363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute naltrexone treatment
Number of subjects: 0
Study 27600363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 38.3 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 1.4 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 0.9 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine 38.9 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 30.6 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.7 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 32.3 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 0.4 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 1.1 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 7.9 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine 13.2 mg/d
Number of subjects: 16555
Study 25841041 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone, Lurasidone, Paliperidone
Number of subjects: 16555
Study 24067385 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous white adipose tissue (SWAT) biopsies pre-intervention
Number of subjects: 20
Study 24067385 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous white adipose tissue (SWAT) biopsies post-intervention
Number of subjects: 20
Study 24067385 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentration
Number of subjects: 20
Study 24067385 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction and weight loss
Number of subjects: 20
Study 24067385 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 20
Study 21957703 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control group
Number of subjects: 30
Study 21957703 — intervention group
Group type: COMPARATOR
Intervention: Yoked group
Number of subjects: 30
Study 19226352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy intervention group (IG: n = 39) receiving approximately 1200 mg of calcium and 7.5 microg of vitamin D(3) per day via fortified dairy products and attending biweekly nutrition counselling sessions
Number of subjects: 101
Study 19226352 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG: n = 36)
Number of subjects: 101
Study 19226352 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-supplemented group (SG: n = 26) receiving a total of 1200 mg calcium per day
Number of subjects: 101
Study 16420280 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. aldosterone (100 microg)
Number of subjects: 9
Study 16420280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15087583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) criteria based on functional and neuropsychological performances
Number of subjects: 90
Study 15087583 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological measures including Letter Cancellation Test
Number of subjects: 90
Study 15087583 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and size of temporal lobe
Number of subjects: 90
Study 15087583 — intervention group
Group type: COMPARATOR
Intervention: Gender, education, apolipoprotein E4 genotype
Number of subjects: 90
Study 11168457 — intervention group
Group type: EXPERIMENTAL
Intervention: Protectamin (45 g daily for 2 weeks)
Number of subjects: 30
Study 11168457 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocal (45 g daily for 2 weeks)
Number of subjects: 30
Study 11168457 — intervention group
Group type: EXPERIMENTAL
Intervention: Protectamin (PMA-induced O2- release)
Number of subjects: 30
Study 11168457 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocal (Spontaneous O2- release)
Number of subjects: 30
Study 11168457 — intervention group
Group type: COMPARATOR
Intervention: Protectamin and Immunocal (Plasma concentrations of TNF-alpha and interleukins 2 and 12)
Number of subjects: 30
Study 9355889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (specifics not provided)
Number of subjects: 663
Study 9355889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 663
Study 8222489 — intervention group
Group type: COMPARATOR
Intervention: 200 mg cefdinir alone
Number of subjects: 0
Study 8222489 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cefdinir with two tablets of iron ion concomitantly
Number of subjects: 0
Study 8222489 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cefdinir with two tablets of iron ion preparation 3 hours later
Number of subjects: 0
Study 3978009 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4.5‐12 micrograms kg‐1 at induction
Number of subjects: 51
Study 3978009 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the patient
Number of subjects: 51
Study 3978009 — intervention group
Group type: COMPARATOR
Intervention: Weight-related dose of buprenorphine, age, sex, body weight, duration of anaesthesia, dose of droperidol or thiopentone
Number of subjects: 51
Study 30853329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration and cold gel pack application
Number of subjects: 0
Study 30853329 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures (Control)
Number of subjects: 0
Study 28027074 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge patient-centred intervention
Number of subjects: 164
Study 28027074 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 164
Study 25820842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (a psychedelic preparation containing N,N-dimethyltryptamine)
Number of subjects: 10
Study 25820842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23504864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Number of subjects: 59
Study 23504864 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 59
Study 21172601 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of the CONSORT statement
Number of subjects: 228
Study 21172601 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant results for efficacy, private funding, primary harms outcome, and anti-infective, antineoplasmatic, or immunosuppressive agents
Number of subjects: 228
Study 19278589 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF levels in survivors
Number of subjects: 29
Study 19278589 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF levels in patients who died
Number of subjects: 29
Study 19278589 — intervention group
Group type: COMPARATOR
Intervention: VEGF levels in healthy control group
Number of subjects: 29
Study 19278589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of VEGF levels with APACHE II score
Number of subjects: 29
Study 19278589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of VEGF levels with PLT
Number of subjects: 29
Study 19278589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of VEGF levels with Alb levels
Number of subjects: 29
Study 17518106 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments of perceived masculinity or femininity by 10 listeners
Number of subjects: 44
Study 17518106 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic measures of talker's speech
Number of subjects: 44
Study 17518106 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analyses of acoustic measures
Number of subjects: 44
Study 15030978 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 60
Study 15030978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11795467 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body hyperthermia (39 degrees C)
Number of subjects: 0
Study 11795467 — intervention group
Group type: COMPARATOR
Intervention: Heat treatment of whole blood in vitro for 2 hours at different temperatures (up to 41 degrees C)
Number of subjects: 0
Study 7846203 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg IV)
Number of subjects: 40
Study 7846203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3073462 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41740
Number of subjects: 29
Study 3073462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30051155 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) for 4 weeks
Number of subjects: 31
Study 30051155 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (CC)
Number of subjects: 31
Study 28342090 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 213
Study 28342090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 213
Study 28342090 — intervention group
Group type: COMPARATOR
Intervention: Standard patch
Number of subjects: 213